journal article·2025-08Open access

High‐Efficiency Carriers’ Separation Strategy Based Ultrasmall‐Bandgap CuWO 4 Sono‐Enhances GSH Antagonism for Cuproptosis Cascade Immunotherapy

Lichao Zhu, Zhisheng Guo, Yu Luo, Haiyan Huang, Kexin Zhang, Bingbing Duan, Renmiao Peng, Haochen Yao, Chao Liang, Kaiyang Wang

Advanced Science· Volume 12· Issue 29

Abstract

Abstract The spatiotemporal sequential treatment strategy of promoting rapid separation of charge carriers, amplifying oxidative stress, increasing the low content of intracellular Cu, enhancing cuproptosis, and cascading activation of immunotherapy is considered one of the most effective techniques for improving the comprehensive therapy of tumors. Herein, copper tungstate (CuWO₄, CWO) nanoparticles with ultrasmall bandgap (1.71 eV) is developed as both piezoelectric‐catalysis agents and copper nanocarriers for synergistic sono‐enhanced cuproptosis. Owing to the unique bandgap microstructure, exposure to ultrasound (US) significantly increase the generation of reactive oxygen species (ROS) and the release of Cu 2+ from CWO. Additionally, ≈60% of glutathione (GSH) and nicotinamide adenine dinucleotide phosphate (NADPH) are consumed in situ, leading to oxidative stress, ferroptosis, and cuproptosis in cancer cells. This cascading approach induces substantial mitochondrial dysfunction and the release of damage‐associated molecular patterns (DAMPs), which promotes immunogenic cell death (ICD) and augments antitumor immunity. Both in vitro and in vivo studies have shown that this sono‐enhanced cuproptosis‐based therapy could effectively suppress tumor growth. Overall, this study investigates a novel Structure‐Function therapeutic approach that combines piezoelectric catalysis, ferroptosis, cuproptosis, and cascade activation of immune regulation, opening up new possibilities for addressing the challenges associated with conventional cuproptosis therapy.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Nanoplatforms for cancer theranostics · Extracellular vesicles in disease · MicroRNA in disease regulation

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Shanghai Engineering Research Center of Pharmaceutical Intelligent Equipment Shanghai Frontiers Science Research Center for Druggability of Cardiovascular Non‐coding RNA Institute for Frontier Medical Technology School of Chemistry and Chemical Engineering Shanghai University of Engineering Science Shanghai 201620 P. R. China

Department of Urology The First Affiliated Hospital of Nanjing Medical University and Jiangsu Province Hospital Nanjing 210029 P. R. China

Hepatobiliary and Pancreatic Surgery Department General Surgery Center First Hospital of Jilin University No.1 Xinmin Street Changchun Jilin 130021 P. R. China

Funding

National Natural Science Foundation of China

References (41)

Show source-provided references
1. 10.1038/s41392-023-01642-x10.1038/s41392-023-01642-x ↗
2. 10.1038/s41467-023-42509-710.1038/s41467-023-42509-7 ↗
3. 10.1002/advs.20230863210.1002/advs.202308632 ↗
4. 10.1016/j.fmre.2022.04.02110.1016/j.fmre.2022.04.021 ↗
5. 10.1016/j.fmre.2022.02.01010.1016/j.fmre.2022.02.010 ↗
6. 10.1002/adfm.20240189710.1002/adfm.202401897 ↗
7. 10.1002/adfm.20230345110.1002/adfm.202303451 ↗
8. 10.1002/adma.20240125210.1002/adma.202401252 ↗
9. 10.1002/anie.20210270310.1002/anie.202102703 ↗
10. 10.1002/anie.20230214610.1002/anie.202302146 ↗
11. 10.1002/adma.20230872610.1002/adma.202308726 ↗
12. 10.1002/adma.20230426210.1002/adma.202304262 ↗
13. 10.1002/adma.20220825610.1002/adma.202208256 ↗
14. 10.1002/adma.20220592410.1002/adma.202205924 ↗
15. 10.1038/s41422-022-00653-710.1038/s41422-022-00653-7 ↗
16. 10.1002/advs.20240251610.1002/advs.202402516 ↗
17. 10.1016/j.indcrop.2025.12090210.1016/j.indcrop.2025.120902 ↗
18. 10.1038/s41419-023-05639-w10.1038/s41419-023-05639-w ↗
19. 10.1038/s41418-023-01125-010.1038/s41418-023-01125-0 ↗
20. 10.1002/advs.20230369410.1002/advs.202303694 ↗
21. 10.1038/s41392-022-01014-x10.1038/s41392-022-01014-x ↗
22. 10.1002/adma.20221226710.1002/adma.202212267 ↗
23. 10.1038/s41571-024-00876-010.1038/s41571-024-00876-0 ↗
24. 10.1002/smll.20240114710.1002/smll.202401147 ↗
25. 10.1126/sciadv.abl550810.1126/sciadv.abl5508 ↗
26. 10.1016/j.ccr.2020.21347410.1016/j.ccr.2020.213474 ↗
27. 10.1016/j.bbamem.2024.18430610.1016/j.bbamem.2024.184306 ↗
28. 10.1002/adma.20230064810.1002/adma.202300648 ↗
29. 10.1016/j.cej.2024.15012610.1016/j.cej.2024.150126 ↗
30. 10.1002/adma.20231142910.1002/adma.202311429 ↗
31. 10.1016/j.apcata.2024.11984710.1016/j.apcata.2024.119847 ↗
32. 10.1021/acs.nanolett.1c0131310.1021/acs.nanolett.1c01313 ↗
33. 10.1002/smtd.20240001810.1002/smtd.202400018 ↗
34. 10.1016/j.fmre.2022.10.00110.1016/j.fmre.2022.10.001 ↗
35. 10.1038/s41467-024-47549-110.1038/s41467-024-47549-1 ↗
36. 10.1016/j.pmatsci.2024.10137510.1016/j.pmatsci.2024.101375 ↗
37. 10.1038/s41589-022-01159-410.1038/s41589-022-01159-4 ↗
38. 10.1002/anie.20230770610.1002/anie.202307706 ↗
39. Sun S. · ACS Nano · 2024 · 18
40. 10.1016/j.fmre.2021.10.00710.1016/j.fmre.2021.10.007 ↗
41. 10.1038/s41467-023-40954-y10.1038/s41467-023-40954-y ↗